Replies to post #247617 on Biotech Values

[dewophile]

I’ve long maintained that while Covid delayed enrollment for RSV it was a net boon for a company like Enanta developing an antiviral because awareness and more so the diagnostic infrastructure was a barrier commercially, and both are mitigated since Covid